tbuckley/cabot-search huggingface dataset:
P2-226: The Portuguese experience with pemetrexed (ALIMTA) in second line treatment of non-small cell lung cancer
Authors: António M. Araujo, Fernando Barata, Bárbara Parente, Sónia Rego, Encarnação Teixeira, Maria J. Melo, Henrique Queiroga, João Cunha, José Duarte
Journal: Journal of Thoracic Oncology (2007)
Efficacy of the Olyset Duo net against insecticide-resistant mosquito vectors of malaria
Authors: Corine Ngufor, Raphael N’Guessan, Josias Fagbohoun, Damien Todjinou, Abibath Odjo, David Malone, Hanafy Ismail, Martin Akogbeto, Mark Rowland
Journal: Science Translational Medicine (2016)

Olyset Duo, a bed net treated with a mixture of the insecticides pyriproxyfen and permethrin, provides improved control of mosquito vectors of malaria in regions of high insecticide resistance.
Perceptions of Disease State, Treatment Expectations, and Prognosis Among Patients with Myelodysplastic Syndromes.
Authors: Mikkael A. Sekeres, Jaroslaw P. Maciejewski, Alan F List, David P Steensma, Andrew Artz, Arlene S. Swern, Paul Scribner, John Huber, Richard Stone
Journal: Blood (2009)
Panitumumab (pmab) in patients (pts) with chemorefractory metastatic colorectal cancer (mCRC): Final analysis from a community-based, observational study (VECTOR) in Germany.
Authors: Christian A. Lerchenmuller, Matthias Groschek, Hendrik Kroening, Burkhard Scheuer, Martina Stauch, Anja Kuhn, Eva Hellebrand, Ursula Vehling-Kaiser
Journal: Journal of Clinical Oncology (2013)

550 Background: Pmab monotherapy significantly improves progression-free survival versus best supportive care in pts with chemorefractory KRAS wild-type (WT) mCRC. This study evaluated the efficacy and safety of pmab in routine clinical practice in Germany. Methods: To ensure a representative sample, eligibility criteria were largely unrestricted. Consenting pts were &gt;18 years old, had histologically confirmed KRAS WT mCRC, &gt;4 weeks pmab therapy, failure of fluoropyrimidine-, oxaliplatin- and irinotecan-containing chemotherapy (CTx) regimens, and women of child-bearing age received contraception. Predefined endpoints were overall response rate (ORR; investigator`s assessment) and skin toxicity (NCI Common Terminology Criteria for Adverse Events v3.0). Results: A total of 428 pts were included in the full analysis set. At the start of pmab therapy, median age was 69 (range 22-89) years, 268 pts (63%) were male and 343 (80%) had an ECOG performance status of 0-1. Overall, 400 pts (93%) had undergone prior surgery and 154 (36%) had received ≥1 cycle of adjuvant CTx. Pts had received a median of 3 cycles (range: 1‑12) of prior CTx for mCRC. The most common regimens were FOLFOX/FOLFIRI ±antibody therapy; 65% of regimens were given with palliative, 32% with curative/palliative and 3% with curative intent. The median pmab dose was 6 mg/kg (range 2.4-7.2) q2w for a median of 8 (range 2‑45) cycles, with 143 pts (33%) receiving &gt;10 cycles. The ORR during pmab therapy was 20% (complete response: n=7 [2%]; partial response: n=77 [18%]); disease control (including stable disease) was achieved in 261 pts (61%). Skin reactions occurred in 324 pts (67%) with 52% experiencing a maximum grade ≥2. Most pts had some type of rash (48% acne, 5% desquamation, 4% hand-foot skin reaction, 1% erythema multiforme). Overall, 21% of pts had other toxicities. Three serious adverse drug reactions (infection/fever; thrombosis/embolism; erythema multiforme) and two grade 1 infusion reactions were reported. Conclusions: In this observational study, pmab monotherapy had efficacy at least as good as was seen in the randomised pmab trial and safety was also similar.
A population-based evaluation of incidence trends in oropharynx cancer (OP) focusing on socioeconomic status (SES), sex, and race/ethnicity.
Authors: A. D. Colevas, C. A. Clarke, D. Lichtensztajn, E. T. Chang
Journal: Journal of Clinical Oncology (2010)

5526 Background: Oropharynx cancer incidence is increasing among males. Methods: To better understand this trend according to SES, we obtained from the population-based California Cancer Registry (CCR) data from 1988 to 2007 on SCCHN patients. For 1990-1992 and 1998-2002, we determined neighborhood SES using an index incorporating neighborhood-level averages of education, income, occupation, and cost of living based on the 1990 and 2000 U.S. Censuses. The CCR assigns patients into SES quintiles based on the statewide distribution of the index; SES quintiles were then collapsed for this analysis into two groups: lower SES (quintiles 1-3) and higher SES (quintiles 4-5). Results: Between 1988 and 2007 the only race/ethnicity- and sex-specific subgroup that demonstrated a significant increase in incidence was non-Hispanic white males with OP. The incidence rate for this group increased monotonically from 4.5 per 100,000 (95% CI: 4.3-4.8) in 1988-92 to 6.7 (95% CI: 6.5-6.9) in 2003-2007. Log-linear joinpoint regression analysis demonstrated an annual percentage change (APC) of 1% from 1988 to 1996 and 4% thereafter. The rising incidence in NH white males was independent of SES. Only low- SES NH black males demonstrated a large decrease trend in the incidence of OP SCC between 1988-1992 and 1998-2002, from 7.9 (95% CI: 6.9-9.1) to 6.3 (95% CI: 5.5-7.3); APC=−1.9%. This drop was similar to the declining trends seen in non-HPV-related head and neck sites for NH black males. Conclusions: Population-based data from California suggest that the rise in incidence of HPV-related tumors based upon the OP site is largely isolated to NH white males and is largely independent of SES. We surmise that the opposite trend seen in low-SES NH black males with OP is related to a relative delay in this population's reduction in tobacco consumption as a competing etiology of OP SCC. Future studies of the biological, behavioral, and environmental risks for HPV-related OP SCC should consider the particular risks of NH white males. Detailed data concerning incidence trends by site, sex, race/ethnicity, SES, and geography will be presented. No significant financial relationships to disclose.
PANCREOX: A Randomized Phase III Study of Fluorouracil/Leucovorin With or Without Oxaliplatin for Second-Line Advanced Pancreatic Cancer in Patients Who Have Received Gemcitabine-Based Chemotherapy
Authors: Sharlene Gill, Yoo-Joung Ko, Christine Cripps, Annie Beaudoin, Sukhbinder Dhesy-Thind, Muhammad Zulfiqar, Pawel Zalewski, Thuan Do, Pablo Cano, Wendy Yin Han Lam, Scot Dowden, Helene Grassin, John Stewart, Malcolm Moore
Journal: Journal of Clinical Oncology (2016)

Purpose The standard of care for second-line therapy in patients with advanced pancreatic cancer after gemcitabine-based therapy is not clearly defined. The CONKO-003 phase III study reported a survival benefit with second-line fluorouracil (FU) and oxaliplatin using the oxaliplatin, folinic acid, and FU (OFF) regimen. 1 PANCREOX was a phase III multicenter trial to evaluate the benefit of FU and oxaliplatin administered as modified FOLFOX6 (mFOLFOX6; infusional fluorouracil, leucovorin, and oxaliplatin) versus infusional FU/leucovorin (LV) in this setting. Patients and Methods Patients with confirmed advanced pancreatic cancer who were previously treated with gemcitabine therapy and with an Eastern Cooperative Oncology Group performance status of 0-2 were eligible. A total of 108 patients were randomly assigned to receive biweekly mFOLFOX6 or infusional FU/LV until progression. Progression-free survival (PFS) was the primary end point. Results Baseline patient characteristics were similar in both arms. No difference was observed in PFS (median, 3.1 months v 2.9 months; P = .99). Overall survival (OS) was inferior in patients assigned to mFOLFOX6 (median, 6.1 months v 9.9 months; P = .02). Increased toxicity was observed with the addition of oxaliplatin, with grade 3/4 adverse events occurring in 63% of patients who received mFOLFOX6 and 11% of those who received FU/LV. More patients in the mFOLFOX6 arm withdrew from study due to adverse events than in the FU/LV arm (20% v 2%), whereas the use of postprogression therapy was significantly higher in the FU/LV arm (25% v 7%; P = .015). No significant differences were observed in time to deterioration on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 global health scale. Conclusion No benefit was observed with the addition of oxaliplatin, administered as mFOLFOX6, versus infusional FU/LV in patients with advanced pancreatic cancer previously treated with first-line gemcitabine.
Liver Gene Therapy by Lentiviral Vectors Allows Partial Correction of Two Hemophilia B Dogs and Revert Pre-Existing Anti-Transgene Immunity in Mice
Authors: Alessio Cantore, Andrea Annoni, Martina Damo, Lucia Sergi Sergi, Sara Bartolaccini, Thierry Vandendriessche, Dwight Bellinger, Maria Grazia Roncarolo, Timothy Nichols, Luigi Naldini
Journal: Molecular Therapy (2012)
Prospective evaluation of adherence to a recommended adjuvant activity regimen in stage II and III colorectal cancer patients.
Authors: S. Mewar, J. Nieto, S. Arshad, R. H. Blum, M. L. Grossbard, P. Kozuch
Journal: Journal of Clinical Oncology (2010)

e14015 Background: At least 18 metabolic units of physical activity per week have been shown in prospective analysis to improve disease-free survival and overall mortality for stage II and stage III colon and rectal cancer survivors. The goal of this study is to assess compliance rate of at least 18 METs/week in a community setting. Methods: 48 stage II or III colorectal cancer patients were enrolled in a prospective observational study either 3-4 months after surgery or during the midpoint of adjuvant chemotherapy. At the time of enrollment and at time of follow-up patients were educated about clinical benefits associated with at least 18 metabolic units physical activity/week. A standardized 3-question instrument as used by Meyerhardt et al was used to measure compliance with adjuvant activity recommendations. Based on Meyerhardt (JCO 24 [26]:3535-3542; 2006), the baseline (p0) rate of METS activity 18 will be assumed to be 28%. A 20% increase in compliance by the time the subject has been in the study for six months is expected and so p1 will be 48%. Results: Of 48 enrolled patients 8 patients were lost to follow-up, 1 patient disenrolled, and 16 patients are too early for follow up (less than 6 months on trial prior to data sweep). Among 23 evaluable patients, the median follow-up is 12 months and the median METs/week is 23.68 (mean 24.53; range 2.9-59). 17 evaluable patients (74%) were able to maintain an average of at least 18 MET/hours per week; 4 patients were unable to reach 18 METs at any data collection point (17%) and 8 patients (35%) improved to 18 METs/week with motivational interviewing. Among the 23 evaluable subjects, 5 have experienced disease recurrence; all had stage III disease. 2 of these subjects recorded greater than 18 METs/week; two had less than 18 METs/week; and 1 disenrolled prior to first follow-up questionnaire. Conclusions: Adherence to a goal of 18 METS/week appears to be achievable by a majority of patients in a community setting. No significant financial relationships to disclose.
FIP1L1-PDGFRα D842V, a Novel Panresistant Mutant, Emerges after Treatment of FIP1L1-PDGFRα T674I Eosinophilic Leukemia with Single Agent Sorafenib
Authors: Peter Vandenberghe, Els Lierman, Lucienne Michaux, Pascal Pierre, Peter Marynen, Jan Cools
Journal: Blood (2008)
Myocardial Tissue Characterization By Cardiac MR Imaging In Myelodysplastic Syndromes
Authors: Alessia Pepe, Antonella Meloni, Giancarlo Carulli, Esther Natalie Oliva, Francesco Arcioni, Sergio Storti, Emanuele Grassedonio, Stefania Renne, Massimiliano Missere, Vincenzo Positano, Massimo Lombardi, Michele Rizzo
Journal: Blood (2013)
Data sharing: lessons from Copernicus and Kepler
Authors: Milton Packer
Journal: BMJ (2016)

They did it, and so must we—quickly, reliably, and respectfully 

To understand the workings of science, pick up a copy of De Revolutionibus Orbium Coelestium. Published with great reluctance by the astronomer Nicolaus Copernicus in 1543, the book puts forth a compelling argument for a heliocentric universe. Turn the pages and you will see the book is filled with data. Whose data? Copernicus relied on the data collected by others in addition to his own to formulate his revolutionary theory. Publication of these data subsequently allowed Johannes Kepler to identify discrepancies, which led to his innovative proposal in 1605 that the planets moved in an ellipse (rather than in a circle), an idea that he had previously assumed to be too simple for earlier astronomers to have overlooked. Of course, Kepler presented his data at the same time that he published his conclusions. In contrast, Tycho Brahe (who opposed Copernicus) famously withheld his astronomical data from Kepler because he knew they could be used to confirm Copernicus’s heliocentric model.

The same principles apply to progress in …
Sixty seconds on . . . Department of Health accounts
Authors: Anne Gulland
Journal: BMJ (2016)

Not exactly. The House of Commons Public Accounts Committee has described the Department of Health’s most recent set as “rotten.”1

Well, they are slightly out. They contain details of an unexpected £417m (€500m; $550m) windfall in national insurance contributions that the health department had failed to declare to Her Majesty’s Treasury.2

HM Treasury is not asking for it, probably because the …
Sequential R-CHOP and R-FM Chemotherapy Followed By Autologous Stem Cell Transplantation Results In High Rates Of Long Term Remission In Advanced Follicular Lymphoma
Authors: Enrico Derenzini, Vittorio Stefoni, Beatrice Casadei, Cinzia Pellegrini, Alessandro Broccoli, Stefano Fanti, Letizia Gandolfi, Giulia Stefani, Lisa Argnani, Pier Luigi Zinzani
Journal: Blood (2013)
Tumor Suppressor MiR-29b Targets HDAC4 and Modulates Vorinostat Activity In Multiple Myeloma Cells
Authors: Nicola Amodio, Marzia Leotta, Lavinia Biamonte, Teresa Calimeri, Eugenio Morelli, Umberto Foresta, Maria Teresa Di Martino, Marco Rossi, Emanuela Leone, Antonino Neri, Pierosandro Tagliaferri, Pierfrancesco Tassone
Journal: Blood (2013)
Aggravated Bone Density Decline after Symptomatic Osteonecrosis in Children with Acute Lymphoblastic Leukemia
Authors: Marissa den Hoed, S.M.F. Pluijm, Mariël L. Te Winkel, Hester A. de Groot-Kruseman, Marta Fiocco, Peter M. Hoogerbrugge, J.a. Leeuw, Marrie Bruin, Inge M. van der Sluis, Dorine Bresters, Maarten H. Lequin, Jan C. Roos, A. Veerman, Rob Pieters, Marry M. van den Heuvel-Eibrink
Journal: Blood (2014)
P1-094: Preoperative serum Cyfra 21-1 and CEA help to assess the stage of non-small cell lung cancer before surgery
Authors: Monika Szturmowicz, Piotr Rudzinski, Grazyna Malecka, Beata Broniarek-Samson, Iwona Bestry, Renata Langfort, Tadeusz Orlowski
Journal: Journal of Thoracic Oncology (2007)
Decisional Regret Among Parents of Children With Cancer
Authors: Jennifer W. Mack, Angel M. Cronin, Tammy I. Kang
Journal: Journal of Clinical Oncology (2016)

Purpose Decision making is one of the ways in which parents serve as stewards of their children with cancer, but barriers to informed decision making among parents of children with cancer have been identified. We sought to evaluate the extent to which parents feel satisfied with, or regretful of, decisions made for their child's cancer treatment and to identify factors associated with heightened regret. Methods We surveyed 346 parents of children with cancer within 12 weeks of their initial cancer treatment decision and the children's physicians at Dana-Farber Cancer Institute/Boston Children's Hospital and the Children's Hospital of Philadelphia. Our main outcome measure was heightened regret as measured by the Decisional Regret Scale. Results Sixteen percent of parents (N = 54) met our definition of heightened decisional regret. In a multivariable logistic regression model, race/ethnicity was associated with regret, with black (odds ratio [OR], 6.55; 95% CI, 2.30 to 18.7), Hispanic (OR, 2.15; 95% CI, .69 to 6.65), and other race parents (OR, 4.68; 95% CI, 1.58 to 13.8) at increased risk for regret relative to whites ( P = .001 across all categories). In contrast, parents who reported receiving high-quality information (OR, .45; 95% CI, .23 to .91; P = .03) and detailed prognostic information (OR, .48; 95% CI, .24 to .96; P = .04), who trusted the oncologist completely (OR, .32; 95% CI, .17 to .63; P = .001), and who held their ideal role in decision making (OR, .49; 95% CI, .25 to .95; P = .04) were less likely to experience regret. Conclusion Although many parents are satisfied with decisions made for their children with cancer, racial and ethnic minority parents are at heightened risk for regret. Clinicians may be able to reduce this risk by providing high-quality information, including prognostic information, involving parents in decision making in the ways they wish, and serving as trusted providers.
P1-126: Pathological study of malignant pleural mesothelioma resected with extrapleural pneumonectomy
Authors: Kenzo Hiroshima, Toshikazu Yusa, Toru Kameya, Ichiro Ito, Toshiaki Kawai, Kou Kaneko, Chikabumi Kadoyama, Hirohisa Kishi, Takehiko Fujisawa, Yukio Nakatani
Journal: Journal of Thoracic Oncology (2007)
Long-Term Outcome of Endoscopic Balloon Dilation in Obstructive Gastroduodenal Crohn's Disease
Authors: T Matsui, S Hatakeyama, K Ikeda, T Yao, K Takenaka, T Sakurai
Journal: Endoscopy (1997)

Background and Study Aims: Although balloon dilation is widely used in nonmalignant pyloric stenosis, little information is available on either the short-term or long-term results of this type of therapy in patients with obstructive gastroduodenal Crohn's disease.
Monitoring vitamin D in the patient with melanoma: impact of sun avoidance on vitamin D levels of patients with melanoma at a U.K. tertiary-referral melanoma service
Authors: M.C.I. Lo, J. Maraka, J. Garioch, W.G. John, M. Moncrieff
Journal: British Journal of Dermatology (2016)

Clinicians across specialties are increasingly aware of health risks associated with vitamin D deficiency (VitD-).The link to bone health is obvious, but there is mounting evidence of associations with disorders including autoimmune and cardiovascular, diabetes, and various cancers (1).Vitamin D is endogenously synthesised in the skin by ultraviolet radiation or orally ingested (2).In the UK, few foods are supplemented with vitamin D, therefore, the main source is sun exposure.Unfortunately, patients in much of the UK are exposed to a UV index <3 for almost
P3-173: Effectiveness of 45 Gy hypofractionated radiotherapy with or without cisplatin in patients with non small cell lung cancer
Authors: Riza Cetingoz, Zumre A. Alicikus, Ayse N. Demiral, Burcu D. Isman, Betul Bakis, Munir Kinay
Journal: Journal of Thoracic Oncology (2007)
First-cycle rash as a clinical marker in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line chemotherapy (CT) plus cetuximab: Efficacy by histology.
Authors: K. J. O'Byrne, J. Von Pawel, I. Vynnychenko, P. Zatloukal, F. De Marinis, W. E. Eberhardt, L. G. Paz-Ares, K. Schumacher, U. Gatzemeier, R. Pirker
Journal: Journal of Clinical Oncology (2010)

7556 Background: The phase III FLEX study demonstrated that adding cetuximab to first-line CT significantly improved overall survival (OS), compared with CT only, in patients with NSCLC of all histological subtypes. The occurrence of first-cycle rash was associated with better outcome in patients treated with CT plus cetuximab in this setting. The association of first-cycle rash and outcome was further investigated in the subgroups of patients with squamous cell carcinoma (SCC) and adenocarcinoma (AC). Methods: FLEX study patients (pts) were randomized to receive up to six, 21-day cycles of cisplatin 80 mg/m2 day 1, and vinorelbine 25 mg/m2 days 1 and 8, either alone or with cetuximab as a 400 mg/m2 initial dose day 1, then 250 mg/m2/weekly until disease progression or unacceptable toxicity. A landmark analysis was used to investigate associations between efficacy endpoints and the occurrence of acne-like rash in the first 21 days of treatment (first-cycle rash). Pts alive on day 21 were considered to be evaluable. Results: There were 540 pts in the CT only arm and 518 evaluable pts in the CT plus cetuximab arm; of the latter 290 (56%) experienced first-cycle rash. Pts with first-cycle rash in the CT plus cetuximab arm had improved OS compared with pts in the CT only arm (hazard ratio, HR = 0.697 [95% CI: 0.588-0.825] p < 0.0001); median survival time 15.0 vs 10.3 months (mos). First-cycle rash efficacy results by histology showed median survivals of 16.9 vs. 12.8 mos in NSCLC patients with AC and 13.2 vs. 9.6 mos in NSCLC patients with SCC for pts receiving CT plus cetuximab and CT, respectively. Improved clinical outcome for the secondary efficacy endpoints (progression-free survival and response rate) for patients with first-cycle rash compared with no rash was apparent for both SCC and AC patient subgroups. Conclusions: Adding cetuximab to standard first-line CT improved OS over CT only. First-cycle rash is a clinical marker indicating patients who are more likely to derive a significant benefit from the addition of cetuximab to CT, with a highly pronounced increase in survival for NSCLC pts with adeno- and squamous cell carcinomas. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Merck KGaA AstraZeneca, BayerSchering, Boehringer Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Lilly, MedImmune, Merck KGaA, Merck Serono, Novartis, Pfizer, Pierre Fabre Medicament, Roche, sanofi-aventis AstraZeneca, Bayer, BayerSchering, Boehringer Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Lilly, MedImmune, Merck KGaA, Merck Serono, Novartis, Pfizer, Pierre Fabre Medicament, Roche, sanofi-aventis Merck KGaA
Health effects of 9/11 terror attacks continue to grow
Authors: Sophie Arie
Journal: BMJ (2016)

Alex Camacho/Gamma-Rapho/Getty Images

Some 15 years after the terrorist attack on New York on 11 September 2001, at least 1000 people, including many emergency responders, are known to have died from illnesses related to their exposure to toxic dust, and 37 000 people are officially recognised as sick.

In the next five years, the death toll from health problems related …
Endoscopic ultrasound-guided fine-needle aspiration of left adrenal gland masses
Authors: J. DeWitt, M. Alsatie, J. LeBlanc, L. McHenry, S. Sherman
Journal: Endoscopy (2007)

See also: Commentaire de travail de J. DeWitt et al., pp. 65Endoscopy 2007; 39(01): 192-192DOI: 10.1055/s-0032-1306912
The Histone Acetyl-Transferase MOZ Cooperates with the Histone Methyl-Transferase MLL to Regulate HOX Gene Expression in Human Hematopoietic Stem Cells
Authors: Jérôme Paggetti, Romain Aucagne, Arnaud Jacquel, Anne Largeot, Brice Lagrange, Eric Solary, Jean-Noël Bastie, Laurent Delva
Journal: Blood (2008)
P1-263: Renal insufficiency in lung cancer patients. Subgroup analysis of the IRMA study
Authors: Jean-François Morere, Vincent Launay-Vacher, Nicolas Janus, Reza Etessami, Stéphane Oudard, Olivier Rixe, Xavier Pourrat, Philippe Beuzeboc, Joseph Gligorov, Gilbert Deray
Journal: Journal of Thoracic Oncology (2007)
Repression of CMIP transcription by WT1 is relevant to podocyte health
Authors: Anissa Moktefi, Shao-yu Zhang, Pauline Vachin, Virginie Ory, Carole Henique, Vincent Audard, Catherine Rucker-Martin, Elodie Gouadon, Michael Eccles, Andreas Schedl, Laurence Heidet, Mario Ollero, Djillali Sahali, Andre Pawlak
Journal: Kidney International (2016)